Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Juvenile dermatomyositis.

L M Pachman

    Pediatric Clinics of North America
    |October 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Juvenile dermatomyositis (JDMS) is a distinct childhood inflammatory disease. Research suggests genetic predisposition and explores its unique immunologic and pathological features.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.

    Genes and immunity·2015
    Same author

    The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis.

    Arthritis care and research : the official journal of the Arthritis Health Professions Association·2003
    Same author

    Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity.

    Current rheumatology reports·2001
    Same author

    Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele.

    Clinical immunology (Orlando, Fla.)·2001
    Same author

    TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications.

    Arthritis and rheumatism·2000
    Same author

    Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis.

    Clinical and diagnostic laboratory immunology·2000
    Same journal

    Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

    Pediatric clinics of North America·2026
    Same journal

    Advancing Pediatric Dermatology: Innovations in Care and Access.

    Pediatric clinics of North America·2026
    Same journal

    No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

    Pediatric clinics of North America·2026
    Same journal

    Telemedicine and Access to Pediatric Dermatology Care.

    Pediatric clinics of North America·2026
    Same journal

    Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

    Pediatric clinics of North America·2026
    Same journal

    Medical Photography's Power to Change Medical Care.

    Pediatric clinics of North America·2026
    See all related articles

    Area of Science:

    • Pediatric Rheumatology
    • Immunology
    • Genetics

    Background:

    • Childhood myositis presents with muscle enzyme elevation, weakness, and inflammation.
    • Juvenile dermatomyositis (JDMS) is more common than polymyositis (PM) in children, especially females, and features skin involvement.
    • Steroid treatment has significantly reduced JDMS mortality, but calcifications remain a debilitating issue.

    Purpose of the Study:

    • To establish Juvenile dermatomyositis (JDMS) as a distinct disease entity.
    • To investigate potential genetic predispositions, such as HLA-B8 and DR3, in JDMS.
    • To explore the immunologic abnormalities and pathogenetic factors in JDMS.

    Main Methods:

    • Review of clinical characteristics, including cutaneous involvement and demographics.

    Related Experiment Videos

  • Analysis of immunologic markers: natural killer cell activity, complement activation, ANA, and coxsackie B antibodies.
  • Examination of pathological findings, including endothelial cell inclusions and small vessel occlusion.

    • Main Results:

    • JDMS is proposed as a distinct entity, potentially influenced by genetic factors (HLA-B8, DR3).
    • Immunologic findings include impaired natural killing, complement activation, and positive ANA; Jo-1 antibodies are absent.
    • Pathology reveals endothelial cell inclusions linked to small vessel occlusion and elevated Factor VIII in active disease.

    Conclusions:

    • JDMS is a distinct disease with potential genetic links.
    • Understanding JDMS immunopathogenesis requires further investigation into immune cell dysfunction and viral associations.
    • Effective treatment strategies, including steroids and other immunosuppressants, require rigorous evaluation for severely affected children.